stockrow
Friday 6 November 2026
Export TENX’s income statement to Excel — free account
Tenax Therapeutics, Inc.
TENX Healthcare Biotechnology
- EPS
- −29.6%
- Free cash flow
- −125.9%
Quarter to June 2026, against a year earlier
1.64
0.17
−9.39%
Follow TENX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to April
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | 0 | — | 12 | 12 | 12 | 0.0% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (44) | (9) | (7) | (8) | (10) | (32) | (11) | (8) | (18) | (53) | (65) | +2.0% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (44) | (9) | (14) | (8) | (10) | (32) | (11) | (8) | (18) | (53) | (65) | +2.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (49,920.00) | (10,017.20) | (14,464.00) | (2,160.00) | (1,520.57) | (2,528.00) | (560.16) | (31.04) | (1.15) | (1.34) | (1.48) | (68.9%) | ||||||
| Cash flow | (17,634.78) | (13,489.44) | (5,499.50) | (1,937.49) | (1,426.60) | (841.57) | (618.95) | (23.81) | (0.97) | (0.91) | (0.90) | (66.6%) | ||||||
| Capex | 80.11 | (5.00) | (7.60) | (0.92) | (0.54) | (0.41) | (0.12) | 0.01 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (17,554.67) | (13,494.44) | (5,507.10) | (1,938.41) | (1,427.14) | (841.98) | (619.07) | (23.79) | (0.97) | (0.91) | (0.90) | (66.6%) | ||||||
| Book value | 19,045.44 | 9,868.78 | 11,771.50 | 967.31 | 711.63 | 329.05 | 81.13 | 32.65 | 6.02 | 2.48 | 2.23 | (63.0%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 39 | 44 | +227.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (16) | (12) | (5) | (8) | (9) | (11) | (11) | (6) | (15) | (36) | (46) | +9.5% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 | (36.5%) | ||||||
| Free cash flow | (16) | (12) | (6) | (8) | (9) | (11) | (11) | (6) | (15) | (36) | (46) | +9.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 7 | 7 | 12 | 4 | 5 | 4 | 1 | 8 | 92 | 97 | 114 | +33.1% | |||||
| Net debt | (13) | (8) | (13) | (5) | (7) | (6) | (2) | (10) | (95) | (98) | (118) | +24.8% | ||||||
| Shareholders’ equity | 17 | 9 | 12 | 4 | 5 | 4 | 1 | 8 | 92 | 97 | 114 | +21.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (91.20) | (53.20) | (121.79) | (85.21) | (148.88) | (505.01) | (235.14) | (102.20) | (32.48) | (52.36) | (57.02) | +38.8 pt | |||||
| ROIC | (852.44) | (498.28) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +852.4 pt | ||||||
| ROE | (113.26) | (67.94) | (136.97) | (108.01) | (234.61) | (732.21) | (385.12) | (160.80) | (35.17) | (55.64) | (59.80) | +57.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 11 | 8 | 10 | 10 | 10 | 9 | 8 | 6 | 6 | 16 | — | +4.3% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Apr 2015 · latest quarter Jun 2015 · fundamentals updated 2 Nov 2026
Tenax Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CSBR Champions Oncology, Inc. | $66.3M | — (loss-making) | — (loss-making) | +8.84% (above 0%: growing) | n/m | −198.74% (below 0%: shrinking) | 50.54% | (2.69%) | Compare |
| CNXU Conexeu Sciences Inc. | $65.4M | — (loss-making) | — | — | n/m | −1,084.33% (below 0%: shrinking) | — | 0.00% | Compare |
| MAIA MAIA Biotechnology, Inc. | $64.2M | — (loss-making) | — | — | n/m | −63.23% (below 0%: shrinking) | — | 0.00% | Compare |
| CING Cingulate Inc. | $61.7M | — (loss-making) | — | — | n/m | −24.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FBIO Fortress Biotech, Inc. | $61.4M | 0.6× | 0.8× | +14.04% (above 0%: growing) | n/m | −115.37% (below 0%: shrinking) | 67.18% | (53.46%) | Compare |
| TENX Tenax Therapeutics, Inc. | $61.0M | — (loss-making) | — | −77.98% (below 0%: shrinking) | n/m | −125.93% (below 0%: shrinking) | 0.00% | 0.00% | |
| CRDF Cardiff Oncology, Inc. | $58.8M | — (loss-making) | — (loss-making) | −14.05% (below 0%: shrinking) | n/m | −41.36% (below 0%: shrinking) | 100.00% | (9,245.19%) | Compare |
| TELO Telomir Pharmaceuticals, Inc. | $57.5M | — (loss-making) | — | — | n/m | −45.34% (below 0%: shrinking) | — | 0.00% | Compare |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | $55.3M | — (loss-making) | — (loss-making) | −92.09% (below 0%: shrinking) | n/m | −78.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $61.5M | — | — | −2.61% | — | −70.87% | 50.54% | 0.00% |
Pay and ownership Proxy statement filed 22 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 8.08m | 21.67m | 0.73 |
| 2024 | 7.40m | 7.70m | 0.37 |
| 2023 | 644.77k | 515.68k | 1.00 |
Ownership
Directors and executive officers, together
10.81%
Entities advised or subadvised by T. Rowe Price Associates, Inc.
12.75%
Entities Associated with Venrock Healthcare Capital Partners
9.99%
Vivo Opportunity Fund Holdings, L.P.
9.99%
Biotechnology Value Fund, L.P. and affiliates
9.99%
RTW Investments, LP
9.99%
Entities of Janus Henderson Investors
9.99%
Entities Affiliated with Vestal Point Capital, LP
8.76%
Christopher T. Giordano
5.86%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement